MA46452B1 - Composés de benzo[b]thiophéne en tant qu'agonistes de sting - Google Patents
Composés de benzo[b]thiophéne en tant qu'agonistes de stingInfo
- Publication number
- MA46452B1 MA46452B1 MA46452A MA46452A MA46452B1 MA 46452 B1 MA46452 B1 MA 46452B1 MA 46452 A MA46452 A MA 46452A MA 46452 A MA46452 A MA 46452A MA 46452 B1 MA46452 B1 MA 46452B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- general formula
- benzo
- thiophene compounds
- sting agonists
- Prior art date
Links
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 title 1
- 229940044665 STING agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 239000013543 active substance Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000014567 type I interferon production Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne des composés de formule générale (la), des composés de formule générale (la'), des composés de formule générale (lb), des composés de formule générale (lb'), des composés de formule générale (i), des composés de formule générale (i'), et leurs sels pharmaceutiquement acceptables, où r 1 , r 2 , r 3 , r 4 , r 5 , r 6 , r 8 , r 9 , x 1 , x 2 , et x 3 sont définis dans la description, qui peuvent être utiles en tant qu'inducteurs de la production d'interféron de type i, spécifiquement en tant qu'agents actifs sting. L'invention concerne également des procédés pour la synthèse et l'utilisation de ces composés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404062P | 2016-10-04 | 2016-10-04 | |
| PCT/US2017/054688 WO2018067423A1 (fr) | 2016-10-04 | 2017-10-02 | Composés de benzo [ b ] thiophène en tant qu'agonistes de piqûre |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46452A MA46452A (fr) | 2021-04-07 |
| MA46452B1 true MA46452B1 (fr) | 2021-10-29 |
Family
ID=60084122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46452A MA46452B1 (fr) | 2016-10-04 | 2017-10-02 | Composés de benzo[b]thiophéne en tant qu'agonistes de sting |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US10414747B2 (fr) |
| EP (1) | EP3523287B1 (fr) |
| JP (1) | JP6636673B2 (fr) |
| KR (1) | KR102312721B1 (fr) |
| CN (1) | CN110036001B (fr) |
| AR (1) | AR109788A1 (fr) |
| AU (1) | AU2017339418C1 (fr) |
| CA (1) | CA3038903C (fr) |
| CL (1) | CL2019000902A1 (fr) |
| CO (1) | CO2019003349A2 (fr) |
| CR (1) | CR20190168A (fr) |
| CY (1) | CY1124837T1 (fr) |
| DK (1) | DK3523287T3 (fr) |
| DO (1) | DOP2019000083A (fr) |
| EA (1) | EA037626B1 (fr) |
| EC (1) | ECSP19026680A (fr) |
| ES (1) | ES2893532T3 (fr) |
| GE (2) | GEP20217285B (fr) |
| HR (1) | HRP20211617T1 (fr) |
| HU (1) | HUE056502T2 (fr) |
| IL (1) | IL265678B2 (fr) |
| JO (1) | JOP20190070B1 (fr) |
| LT (1) | LT3523287T (fr) |
| MA (1) | MA46452B1 (fr) |
| MD (1) | MD3523287T2 (fr) |
| MX (1) | MX386187B (fr) |
| MY (1) | MY196383A (fr) |
| NI (1) | NI201900029A (fr) |
| PE (1) | PE20190705A1 (fr) |
| PH (1) | PH12019500712B1 (fr) |
| PL (1) | PL3523287T3 (fr) |
| PT (1) | PT3523287T (fr) |
| RS (1) | RS62410B1 (fr) |
| SG (1) | SG10202008647TA (fr) |
| SI (1) | SI3523287T1 (fr) |
| TN (2) | TN2020000158A1 (fr) |
| TW (1) | TWI796306B (fr) |
| UA (1) | UA125223C2 (fr) |
| WO (1) | WO2018067423A1 (fr) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3429596B1 (fr) | 2016-03-18 | 2022-08-31 | Immune Sensor, LLC | Composés di-nucléotides cycliques et leurs procédés d'utilisation |
| WO2018009648A1 (fr) | 2016-07-06 | 2018-01-11 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
| UA125223C2 (uk) * | 2016-10-04 | 2022-02-02 | Мерк Шарп І Доум Корп. | СПОЛУКИ БЕНЗО[b]ТІОФЕНУ ЯК АГОНІСТИ STING |
| US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| SG11201908813QA (en) | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
| EP3661499A4 (fr) * | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme Corp. | Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b |
| CA3071538A1 (fr) * | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | Agonistes benzo[b]thiophene de sting pour le traitement du cancer |
| US11638716B2 (en) | 2017-08-31 | 2023-05-02 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| WO2019051488A1 (fr) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
| WO2019051489A1 (fr) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
| US12178851B2 (en) * | 2017-10-05 | 2024-12-31 | Glaxosmithkline Intellectual Property Development Limited | Methods for administering STING agonists |
| TW201922263A (zh) | 2017-11-10 | 2019-06-16 | 日商武田藥品工業股份有限公司 | 干擾素基因刺激蛋白之調節化合物，及製造和使用方法 |
| WO2019109001A1 (fr) | 2017-12-01 | 2019-06-06 | The Texas A&M University System | Traitement anti-sens du syndrome d'angelman |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| KR102755259B1 (ko) * | 2018-04-03 | 2025-01-15 | 머크 샤프 앤드 돔 엘엘씨 | Sting 효능제로서의 벤조티오펜 및 관련 화합물 |
| EP3774765A4 (fr) * | 2018-04-03 | 2021-12-29 | Merck Sharp & Dohme Corp. | Composés aza-benzothiophènes utilisés en tant qu'agonistes de sting |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019211799A1 (fr) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle |
| GB201807924D0 (en) * | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| US10947227B2 (en) | 2018-05-25 | 2021-03-16 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
| CA3106110A1 (fr) | 2018-07-10 | 2020-01-16 | Sperovie Biosciences, Inc. | Composes, compositions et procedes pour le traitement d'une maladie |
| WO2020010451A1 (fr) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Amides imidazolyle hétéroaromatiques fusionnés, compositions et utilisations de ceux-ci en tant qu'agonistes de sting |
| EP4667493A2 (fr) * | 2018-07-26 | 2025-12-24 | Bristol-Myers Squibb Company | Polythérapie à base de lag-3 pour le traitement du cancer |
| WO2020028565A1 (fr) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Composés hétéroaryles tricycliques en tant qu'activateurs de sting |
| WO2020028566A1 (fr) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Composés amides hétéroaryles en tant qu'activateurs de sting |
| WO2020028097A1 (fr) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique |
| SMT202500141T1 (it) | 2018-09-06 | 2025-05-12 | Daiichi Sankyo Co Ltd | Coniugati farmaco-anticorpo di derivati dinucleotidici ciclici |
| TW202446772A (zh) | 2018-10-11 | 2024-12-01 | 日商小野藥品工業股份有限公司 | Ｓｔｉｎｇ促效化合物 |
| EP4371987B9 (fr) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Composés de 6-azabenzimidazole substitués utilisés en tant qu'inhibiteurs de hpk1 |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| CN111393404B (zh) * | 2019-01-02 | 2023-02-17 | 中国科学院上海药物研究所 | 一类苯并噻吩类化合物及其药物组合物及应用 |
| CN111393405B (zh) * | 2019-01-02 | 2022-11-25 | 中国科学院上海药物研究所 | 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用 |
| WO2020146237A1 (fr) | 2019-01-07 | 2020-07-16 | Incyte Corporation | Composés d'amide d'hétéroaryle en tant qu'activateurs de sting |
| WO2020165600A1 (fr) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Conjugués peptide-ligand bicyclique et leurs utilisations |
| EP3935065A1 (fr) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| KR102885020B1 (ko) * | 2019-04-30 | 2025-11-11 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 벤조티오펜 화합물, 이의 제조 방법 및 용도 |
| CN111848573B (zh) * | 2019-04-30 | 2023-04-07 | 四川科伦博泰生物医药股份有限公司 | 苯并噻吩酰胺类化合物及其制备方法和用途 |
| CN111848572B (zh) * | 2019-04-30 | 2023-03-31 | 四川科伦博泰生物医药股份有限公司 | 酰胺类化合物及其制备方法和用途 |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| WO2020237025A1 (fr) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1 |
| WO2020263830A1 (fr) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Protéines de fusion flt3l-fc et procédés d'utilisation |
| EP3993834A1 (fr) | 2019-07-05 | 2022-05-11 | Tambo, Inc. | Agents bioorthogonaux de trans-cyclooctène et leurs utilisations dans le traitement du cancer et l'immunothérapie |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| JP2022543086A (ja) | 2019-08-02 | 2022-10-07 | メルサナ セラピューティクス インコーポレイテッド | がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物 |
| EP4017476A1 (fr) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Formulations pharmaceutiques de ténofovir alafénamide |
| AU2020332005B2 (en) * | 2019-08-21 | 2024-05-23 | The Scripps Research Institute | Monocyclic agonists of stimulator of interferon genes sting |
| JP7414965B2 (ja) * | 2019-08-21 | 2024-01-16 | ザ スクリプス リサーチ インスティテュート | インターフェロン遺伝子の刺激因子ｓｔｉｎｇの二環式アゴニスト |
| CA3149557A1 (fr) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Vaccins contre le virus de l'hepatite b et methodes de traitement du vhb |
| CN112724127B (zh) * | 2019-10-28 | 2023-02-17 | 中国科学院上海药物研究所 | 五元杂环氧代羧酸类化合物及其医药用途 |
| WO2021113765A1 (fr) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Méganucléases modifiées optimisées ayant une spécificité pour une séquence de reconnaissance dans un génome du virus de l'hépatite b |
| WO2021113679A1 (fr) * | 2019-12-06 | 2021-06-10 | Mersana Therapeutics, Inc. | Composés dimères utilisés en tant qu'agonistes de sting |
| CA3164751A1 (fr) | 2019-12-18 | 2021-06-24 | Benjamin Joseph MORROW | Composes |
| CA3168368A1 (fr) | 2020-03-06 | 2021-09-10 | Masayuki Ishizaki | Conjugue anticorps-medicament comprenant un nouveau derive de dinucleotide cyclique |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| CN116196435B (zh) | 2020-04-02 | 2025-12-02 | 梅尔莎纳医疗公司 | 包含sting激动剂的抗体药物缀合物 |
| US20230141284A1 (en) * | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| WO2021205631A1 (fr) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | Composé agoniste de sting |
| US12390537B2 (en) | 2020-05-13 | 2025-08-19 | Massachusetts Institute Of Technology | Compositions of polymeric microdevices and methods of use thereof in cancer immunotherapy |
| CN113861161A (zh) * | 2020-06-30 | 2021-12-31 | 上海海和药物研究开发股份有限公司 | 一种芳基并芳杂环衍生物及其制备方法和用途 |
| ES3054072T3 (en) | 2020-08-07 | 2026-01-29 | Gilead Sciences Inc | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| US20230256109A1 (en) | 2020-08-07 | 2023-08-17 | Tambo, Inc. | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy |
| CA3191395A1 (fr) | 2020-09-02 | 2022-03-10 | Daiichi Sankyo Company, Limited | Nouvelle endo-beta-n-acetylglucosaminidase |
| IL302390A (en) | 2020-11-09 | 2023-06-01 | Takeda Pharmaceuticals Co | Drug antibody conjugates |
| CN113429384B (zh) * | 2021-05-12 | 2022-04-08 | 中山大学附属第五医院 | 一类干扰素基因刺激因子靶向的放射性pet显像剂 |
| JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ， インコーポレイテッド | ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ |
| WO2022245671A1 (fr) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Méthodes d'utilisation de protéines de fusion flt3l-fc |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2022271659A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359413A1 (fr) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
| WO2023284719A1 (fr) * | 2021-07-13 | 2023-01-19 | Nanjing University | Conjugué de pt et son utilisation |
| CN113429387B (zh) * | 2021-07-27 | 2022-10-28 | 中国药科大学 | 一种苯并[b]硒吩类STING调控剂、其制备方法及用途 |
| CN115772154B (zh) * | 2021-09-08 | 2024-04-30 | 上海交通大学 | 一类含有氘取代的苯并噻吩类衍生物及其制备与用途 |
| IL315341A (en) | 2022-03-02 | 2024-10-01 | Daiichi Sankyo Co Ltd | METHOD FOR PRODUCING Fc-CONTAINING MOLECULE |
| WO2023211930A1 (fr) * | 2022-04-25 | 2023-11-02 | The Regents Of The University Of Michigan | Composés de modulation immunitaire à double fonction, formulations et utilisations associées |
| CN119212984A (zh) * | 2022-04-25 | 2024-12-27 | 密歇根大学董事会 | Sting激动剂、制剂及其用途 |
| WO2024048490A1 (fr) | 2022-08-29 | 2024-03-07 | 第一三共株式会社 | Conjugué anticorps-médicament comprenant une région fc mutante |
| WO2024175086A1 (fr) * | 2023-02-24 | 2024-08-29 | 深圳真实生物医药科技有限公司 | Agoniste de sting aryle tricyclique et son utilisation |
| CN116354922B (zh) * | 2023-03-31 | 2025-04-25 | 药康众拓(江苏)医药科技有限公司 | 氘代苯并噻吩类化合物及其药物组合物和用途 |
| EP4687796A1 (fr) | 2023-04-05 | 2026-02-11 | Massachusetts Institute of Technology | Systèmes polymères hybrides et procédés d'utilisation associés |
| WO2025007743A1 (fr) * | 2023-07-04 | 2025-01-09 | Primelink Biotherapeutics (Shenzhen) Co., Ltd. | Agonistes de sting et leurs utilisations |
| WO2025096584A1 (fr) * | 2023-10-30 | 2025-05-08 | The Regents Of The University Of Michigan | Agonistes de sting, compositions et utilisations associées |
| WO2025096619A1 (fr) * | 2023-10-30 | 2025-05-08 | The Regents Of The University Of Michigan | Composés de modulation immunitaire à double fonctionnement, formulations et leurs utilisations |
| WO2025240242A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies avec ribavirine |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies avec de la ribavirine |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| CN121293183A (zh) * | 2025-12-15 | 2026-01-09 | 北京悦康科创医药科技股份有限公司 | 含有苯并噻吩结构用于激活sting通路的佐剂脂质及其组合物 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB532822A (en) * | 1939-08-11 | 1941-01-31 | John David Kendall | Improvements in and relating to the production of ª‡-coumarilyl and ª‡-thionaphthenoyl-acetic acid esters |
| GB1383114A (en) * | 1972-06-22 | 1975-02-05 | English Electric Valve Co Ltd | Magnetrons |
| US4342691A (en) | 1980-04-28 | 1982-08-03 | American Cyanamid Company | ω-Heteroaroyl(propionyl or butyryl)-L-prolines |
| US4299769A (en) * | 1980-04-28 | 1981-11-10 | American Cyanamid Company | ω-Heteroaroyl(propionyl or butyryl)-L-prolines |
| US4342689A (en) | 1980-04-28 | 1982-08-03 | American Cyanamid Company | ω-Heteroaroyl(propionyl or butyryl)-L-prolines |
| US4342690A (en) | 1980-04-28 | 1982-08-03 | American Cyanamid Company | ω-Heteroaroyl(propionyl or butyryl)-L-prolines |
| EP0146243A1 (fr) | 1983-10-31 | 1985-06-26 | Merck Frosst Canada Inc. | Inhibiteurs de la lipoxygénase |
| EP0350990B1 (fr) * | 1988-07-11 | 1995-09-20 | Akzo Nobel N.V. | Dérivés de pyridazinone |
| JPH08502484A (ja) | 1992-10-14 | 1996-03-19 | メルク エンド カンパニー インコーポレーテッド | フィブリノゲンリセプタ拮抗剤 |
| US5569655A (en) | 1993-09-14 | 1996-10-29 | Sterling Winthrop Inc. | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof |
| EP1086091A4 (fr) | 1998-06-03 | 2001-10-10 | Merck & Co Inc | Inhibiteurs de vih integrase |
| US6262055B1 (en) | 1998-06-03 | 2001-07-17 | Merck & Co., Inc. | HIV integrase inhibitors |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| US7288567B2 (en) | 2000-03-24 | 2007-10-30 | Methylgene Inc. | Inhibitors of histone deacetylase |
| WO2002068470A2 (fr) | 2001-02-26 | 2002-09-06 | Pharma Pacific Pty Ltd | Gene induit par l'interferon alpha |
| EP2206517B1 (fr) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Compositions immunostimulantes contenant un anticorps anti-PD-L1 |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| EP2270051B1 (fr) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Anticorps spécifiques de PD-1 et CD3 humains |
| AU2004268012B2 (en) | 2003-09-02 | 2008-11-20 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| JP4887284B2 (ja) | 2004-03-15 | 2012-02-29 | デイビッド・ケイ・アール・カラオリス | 癌細胞の増殖を阻害するための、または癌細胞のアポトーシスを増大させるための方法 |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP1782826A1 (fr) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS, c-diGMP et leurs conjugués utilisés comme adjuvants et leur emploi dans des compositions pharmaceutiques |
| CA2691357C (fr) | 2007-06-18 | 2014-09-23 | N.V. Organon | Anticorps diriges contre le recepteur humain de mort programmee pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP2328919A2 (fr) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Antagonistes de pd-i et procédés de traitement d'une maladie infectieuse |
| CA2998281C (fr) | 2008-09-26 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Anticorps anti-pd-1 humains et leurs utilisations |
| WO2010047774A2 (fr) | 2008-10-20 | 2010-04-29 | The Texas A & M University System | Inhibiteurs de la mycobacterium tuberculosis malate synthase, procédés de marquage et utilisations de ceux-ci |
| EP4331604B9 (fr) | 2008-12-09 | 2025-07-23 | F. Hoffmann-La Roche AG | Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2012068702A1 (fr) * | 2010-11-23 | 2012-05-31 | 中国医学科学院医药生物技术研究所 | Composés de benzo hétérocycliques insaturés à 5 éléments et procédés pour les préparer |
| JP5887947B2 (ja) | 2011-03-28 | 2016-03-16 | ソニー株式会社 | 透明導電膜、ヒータ、タッチパネル、太陽電池、有機ｅｌ装置、液晶装置および電子ペーパ |
| EP2697242B1 (fr) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | Dérivés de nucléosides à substitution 2'-azido et leurs procédés d'utilisation pour le traitement de maladies virales |
| KR20190133790A (ko) | 2011-08-01 | 2019-12-03 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법 |
| CN104507538B (zh) | 2012-06-08 | 2018-04-06 | 艾杜罗生物科技公司 | 癌症免疫疗法的组合物和方法 |
| CN103840995B (zh) | 2012-11-26 | 2017-10-24 | 华为技术有限公司 | Ip报文处理方法、装置及网络系统 |
| KR20150095668A (ko) | 2012-12-13 | 2015-08-21 | 아두로 바이오테크, 인코포레이티드 | 규정된 입체화학을 갖는 환식 퓨린 다이뉴클레오타이드를 포함하는 조성물, 그리고 이의 제조 방법 및 용도 |
| WO2014099941A1 (fr) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro-nucléosides pour le traitement du vhc |
| CN110201155A (zh) | 2012-12-19 | 2019-09-06 | 得克萨斯州立大学董事会 | 哺乳动物的环二核苷酸信号通路的药物靶向 |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| JP2016518140A (ja) | 2013-05-03 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｉ型インターフェロンの環状ジヌクレオチド誘導法 |
| EP2996472B1 (fr) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions et procédés d'inhibition de la signalisation dépendante du « stimulateur des gènes interférons » |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| US9724408B2 (en) | 2013-05-18 | 2017-08-08 | Aduro Biotech, Inc. | Compositions and methods for activating stimulator of interferon gene-dependent signalling |
| WO2015017652A1 (fr) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Cristaux sting et modulateurs associés |
| WO2015077354A1 (fr) * | 2013-11-19 | 2015-05-28 | The University Of Chicago | Utilisation d'un agoniste de sting en tant que traitement anti-cancéreux |
| CA2931146C (fr) | 2013-11-22 | 2022-06-28 | Brock University | Utilisation de dinucleotides cycliques fluores comme adjuvants de vaccin oral |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| WO2015143712A1 (fr) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | Inhibiteurs nucléosidiques substitués en 4' de la transcriptase inverse |
| EP3131914B1 (fr) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c |
| CN103908468B (zh) | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
| MX2016015928A (es) | 2014-06-04 | 2017-03-20 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos ciclicos como moduladores de sting. |
| WO2015189117A1 (fr) | 2014-06-12 | 2015-12-17 | Bayer Pharma Aktiengesellschaft | Dérivés de l'acide 4-oxobutanoïque hétérobicycliques substitués et utilisation desdits dérivés |
| WO2016096174A1 (fr) | 2014-12-16 | 2016-06-23 | Invivogen | Dinucléotides cycliques fluorés utilisables en vue de l'induction des cytokines |
| EP3233191A1 (fr) | 2014-12-16 | 2017-10-25 | Invivogen | Utilisation combinée d'un agent chimiothérapeutique et d'un dinucléotide cyclique pour le traitement du cancer |
| WO2016100261A2 (fr) | 2014-12-17 | 2016-06-23 | Lipogen Llc | Procédé de traitement du cancer avec cgamp ou cgasmp |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JP6692826B2 (ja) * | 2015-03-10 | 2020-05-13 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法 |
| TW201717968A (zh) | 2015-07-14 | 2017-06-01 | 春季銀行製藥公司 | 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物 |
| US10844051B2 (en) | 2015-07-22 | 2020-11-24 | The Royal Institution For The Advancement Of Learning/Mcgill University | Substituted oxazoles for the treatment of cancer |
| UA123701C2 (uk) | 2015-08-13 | 2021-05-19 | Мерк Шарп І Доум Корп. | Циклічні динуклеотидні сполуки як агоністи sting |
| US9809597B2 (en) | 2015-08-20 | 2017-11-07 | The Board Of Trustees Of The Leland Stanford Junior University | Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy |
| US10906930B2 (en) | 2015-10-28 | 2021-02-02 | Chinook Therapeutics, Inc. | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling |
| ES2863225T3 (es) | 2015-12-03 | 2021-10-11 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos purinos como moduladores del sting |
| WO2017100305A2 (fr) | 2015-12-07 | 2017-06-15 | Opi Vi - Ip Holdco Llc | Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation |
| US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| EP3402801B1 (fr) | 2016-01-11 | 2025-08-06 | Innate Tumor Immunity, Inc. | Dinucléotides cycliques pour traiter des affections associées à l'activité sting comme le cancer |
| EP3429596B1 (fr) | 2016-03-18 | 2022-08-31 | Immune Sensor, LLC | Composés di-nucléotides cycliques et leurs procédés d'utilisation |
| WO2017175156A1 (fr) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Amides hétérocycliques utiles en tant que modulateurs de protéine |
| CR20200045A (es) | 2016-04-07 | 2020-03-11 | Glaxosmithkline Ip Dev Ltd | AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472) |
| MA45244A (fr) | 2016-06-13 | 2019-04-17 | Cancer Research Tech Ltd | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 |
| WO2018009466A1 (fr) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations |
| UA125223C2 (uk) * | 2016-10-04 | 2022-02-02 | Мерк Шарп І Доум Корп. | СПОЛУКИ БЕНЗО[b]ТІОФЕНУ ЯК АГОНІСТИ STING |
| CA3071538A1 (fr) * | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | Agonistes benzo[b]thiophene de sting pour le traitement du cancer |
| EP3661499A4 (fr) * | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme Corp. | Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b |
-
2017
- 2017-10-02 UA UAA201904737A patent/UA125223C2/uk unknown
- 2017-10-02 CN CN201780070494.2A patent/CN110036001B/zh active Active
- 2017-10-02 MY MYPI2019001742A patent/MY196383A/en unknown
- 2017-10-02 CR CR20190168A patent/CR20190168A/es unknown
- 2017-10-02 DK DK17784507.0T patent/DK3523287T3/da active
- 2017-10-02 ES ES17784507T patent/ES2893532T3/es active Active
- 2017-10-02 TW TW106134034A patent/TWI796306B/zh not_active IP Right Cessation
- 2017-10-02 LT LTEPPCT/US2017/054688T patent/LT3523287T/lt unknown
- 2017-10-02 RS RS20211230A patent/RS62410B1/sr unknown
- 2017-10-02 WO PCT/US2017/054688 patent/WO2018067423A1/fr not_active Ceased
- 2017-10-02 US US15/722,093 patent/US10414747B2/en active Active
- 2017-10-02 MA MA46452A patent/MA46452B1/fr unknown
- 2017-10-02 EA EA201990846A patent/EA037626B1/ru unknown
- 2017-10-02 EP EP17784507.0A patent/EP3523287B1/fr active Active
- 2017-10-02 GE GEAP201715066A patent/GEP20217285B/en unknown
- 2017-10-02 MX MX2019003829A patent/MX386187B/es unknown
- 2017-10-02 JO JOP/2019/0070A patent/JOP20190070B1/ar active
- 2017-10-02 GE GEAP202115066A patent/GEAP202115066A/en unknown
- 2017-10-02 PH PH1/2019/500712A patent/PH12019500712B1/en unknown
- 2017-10-02 SG SG10202008647TA patent/SG10202008647TA/en unknown
- 2017-10-02 TN TNP/2020/000158A patent/TN2020000158A1/en unknown
- 2017-10-02 PT PT17784507T patent/PT3523287T/pt unknown
- 2017-10-02 HU HUE17784507A patent/HUE056502T2/hu unknown
- 2017-10-02 JP JP2019517943A patent/JP6636673B2/ja active Active
- 2017-10-02 MD MDE20190899T patent/MD3523287T2/ro unknown
- 2017-10-02 CA CA3038903A patent/CA3038903C/fr active Active
- 2017-10-02 AR ARP170102751A patent/AR109788A1/es not_active Application Discontinuation
- 2017-10-02 KR KR1020197012543A patent/KR102312721B1/ko active Active
- 2017-10-02 AU AU2017339418A patent/AU2017339418C1/en active Active
- 2017-10-02 PE PE2019000764A patent/PE20190705A1/es unknown
- 2017-10-02 HR HRP20211617TT patent/HRP20211617T1/hr unknown
- 2017-10-02 SI SI201730918T patent/SI3523287T1/sl unknown
- 2017-10-02 PL PL17784507T patent/PL3523287T3/pl unknown
- 2017-10-02 TN TNP/2020/000159A patent/TN2020000159A1/en unknown
-
2019
- 2019-03-27 IL IL265678A patent/IL265678B2/en unknown
- 2019-04-03 NI NI201900029A patent/NI201900029A/es unknown
- 2019-04-03 CL CL2019000902A patent/CL2019000902A1/es unknown
- 2019-04-03 DO DO2019000083A patent/DOP2019000083A/es unknown
- 2019-04-04 CO CONC2019/0003349A patent/CO2019003349A2/es unknown
- 2019-04-12 EC ECSENADI201926680A patent/ECSP19026680A/es unknown
- 2019-07-16 US US16/513,409 patent/US10703738B2/en active Active
- 2019-07-16 US US16/513,417 patent/US10730849B2/en active Active
-
2021
- 2021-10-22 CY CY20211100924T patent/CY1124837T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46452B1 (fr) | Composés de benzo[b]thiophéne en tant qu'agonistes de sting | |
| MA35753B1 (fr) | Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2 | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| MA42410B1 (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA41251B1 (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
| MA42109B1 (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| MA31849B1 (fr) | Nouveaux dérivés de pyrimidine | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| MA39172A1 (fr) | Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines | |
| MA38175B1 (fr) | Lactames fusionnés à un aryle et hétéroaryle | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
| CY1109992T1 (el) | Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα | |
| UA103329C2 (ru) | Соли соединений-ингибиторов вич | |
| MA32275B1 (fr) | Preparations orales et injectables de composes de tetracycline | |
| MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA38250A1 (fr) | Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie | |
| EA201100350A1 (ru) | Противогрибковые средства | |
| JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| EP3974531A4 (fr) | Arnsi asymétrique pour inhiber l'expression de pd-1 | |
| MA38591A1 (fr) | Héteroaryldihydropyrimidines pontées en position 6 pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b | |
| MA38411A1 (fr) | Inhibiteurs de cdc7 | |
| MA38191A1 (fr) | Composés tricycliques pour inhiber le canal cftr | |
| MA35510B1 (fr) | Composés de pyridazinon et leur utilisation en tant qu'inhibiteurs de la daao |